JP2010504530A - Ｒａｆ阻害剤の標的調節、効果、診断、および／または予後診断のためのバイオマーカー - Google Patents

Ｒａｆ阻害剤の標的調節、効果、診断、および／または予後診断のためのバイオマーカー Download PDF

Info

Publication number
JP2010504530A
JP2010504530A JP2009529376A JP2009529376A JP2010504530A JP 2010504530 A JP2010504530 A JP 2010504530A JP 2009529376 A JP2009529376 A JP 2009529376A JP 2009529376 A JP2009529376 A JP 2009529376A JP 2010504530 A JP2010504530 A JP 2010504530A
Authority
JP
Japan
Prior art keywords
biomarker
gene expression
patient
raf
biomarkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009529376A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010504530A5 (https=
Inventor
ナターシャ・アジーズ
エドワード・モウラー
ダリン・スチュアート
カーラ・ハイセ
キム・アーダレン
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2010504530A publication Critical patent/JP2010504530A/ja
Publication of JP2010504530A5 publication Critical patent/JP2010504530A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2009529376A 2006-09-19 2007-09-19 Ｒａｆ阻害剤の標的調節、効果、診断、および／または予後診断のためのバイオマーカー Pending JP2010504530A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84560106P 2006-09-19 2006-09-19
PCT/US2007/078946 WO2008082730A2 (en) 2006-09-19 2007-09-19 Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013015294A Division JP2013128487A (ja) 2006-09-19 2013-01-30 Ｒａｆ阻害剤の標的調節、効果、診断、および／または予後診断のためのバイオマーカー

Publications (2)

Publication Number Publication Date
JP2010504530A true JP2010504530A (ja) 2010-02-12
JP2010504530A5 JP2010504530A5 (https=) 2010-10-28

Family

ID=39445772

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009529376A Pending JP2010504530A (ja) 2006-09-19 2007-09-19 Ｒａｆ阻害剤の標的調節、効果、診断、および／または予後診断のためのバイオマーカー
JP2013015294A Withdrawn JP2013128487A (ja) 2006-09-19 2013-01-30 Ｒａｆ阻害剤の標的調節、効果、診断、および／または予後診断のためのバイオマーカー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013015294A Withdrawn JP2013128487A (ja) 2006-09-19 2013-01-30 Ｒａｆ阻害剤の標的調節、効果、診断、および／または予後診断のためのバイオマーカー

Country Status (13)

Country Link
US (1) US20100004253A1 (https=)
EP (1) EP2074226A2 (https=)
JP (2) JP2010504530A (https=)
KR (1) KR20090071603A (https=)
CN (1) CN101541977A (https=)
AU (1) AU2007340265B2 (https=)
BR (1) BRPI0716944A2 (https=)
CA (1) CA2662508A1 (https=)
IL (1) IL197450A0 (https=)
MX (1) MX2009002936A (https=)
RU (1) RU2009114745A (https=)
SG (1) SG174826A1 (https=)
WO (1) WO2008082730A2 (https=)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013537544A (ja) * 2010-08-17 2013-10-03 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗癌剤併用療法
JP2015502958A (ja) * 2011-12-09 2015-01-29 オンコメッド ファーマシューティカルズ インコーポレイテッド がんの処置のための併用療法
JP2015536667A (ja) * 2012-12-03 2015-12-24 アルマック・ダイアグノスティクス・リミテッドＡｌｍａｃ Ｄｉａｇｎｏｓｔｉｃｓ Ｌｉｍｉｔｅｄ 癌のための分子診断検査
JP2016528914A (ja) * 2013-08-28 2016-09-23 クラウン バイオサイエンス インコーポレイテッド（タイカン） 対象のマルチキナーゼ阻害剤に対する応答性を予測する遺伝子発現シグネチャ、及びその使用
JP2017533727A (ja) * 2014-10-13 2017-11-16 セルジーン コーポレイション 固形腫瘍の治療方法及び免疫調節療法への臨床的感度の予測因子としてのバイオマーカーの使用
US10260097B2 (en) 2011-06-02 2019-04-16 Almac Diagnostics Limited Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent
US10280468B2 (en) 2014-02-07 2019-05-07 Almac Diagnostics Limited Molecular diagnostic test for predicting response to anti-angiogenic drugs and prognosis of cancer
JP2019518426A (ja) * 2016-04-15 2019-07-04 ジェネンテック， インコーポレイテッド がんの診断及び治療方法
JP2019216716A (ja) * 2013-12-06 2019-12-26 セルジーン コーポレイション びまん性大細胞型ｂ細胞リンパ腫、多発性骨髄腫、及び骨髄癌の治療の薬効を決定するための方法

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
CN103424541B (zh) 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
RU2011102743A (ru) * 2008-06-26 2012-08-10 Дана-Фарбер Кэнсер Инститьют, Инк. (Us) Характерные признаки и детерминанты, связанные с метастазированием, и способы их применения
US8583380B2 (en) 2008-09-05 2013-11-12 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
CN103002911B (zh) 2008-09-26 2015-08-26 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
GB2463401B (en) 2008-11-12 2014-01-29 Caris Life Sciences Luxembourg Holdings S A R L Characterizing prostate disorders by analysis of microvesicles
WO2011109440A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings Biomarkers for theranostics
US20120041274A1 (en) * 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
US8673928B2 (en) 2009-11-18 2014-03-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
US20120045433A1 (en) * 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
RU2565550C2 (ru) 2010-09-24 2015-10-20 Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити Прямой захват, амплификация и секвенирование днк-мишени с использованием иммобилизированных праймеров
EP2444503B1 (en) * 2010-10-20 2016-03-02 Université Joseph Fourier Use of specific genes for the prognosis of lung cancer and the corresponding progonosis method
EP2630237A4 (en) * 2010-10-21 2014-04-09 Oncotherapy Science Inc C18ORF54 PEPTIDES AND VACCINES CONTAINING THEM
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
JP2014516549A (ja) * 2011-06-02 2014-07-17 ノバルティス アーゲー ヘッジホッグ阻害剤療法のためのバイオマーカー
WO2013006495A2 (en) * 2011-07-01 2013-01-10 Dana-Farber Cancer Institute, Inc. Methods of predicting prognosis in cancer
US10378060B2 (en) 2011-10-14 2019-08-13 Dana-Farber Cancer Institute, Inc. ZNF365/ZFP365 biomarker predictive of anti-cancer response
WO2013104104A1 (zh) * 2012-01-09 2013-07-18 苏州工业园区为真生物医药科技有限公司 诊断和预示乳腺癌的标志物
US9428813B2 (en) 2012-03-26 2016-08-30 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services DNA methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
DK2884979T3 (da) 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
TWI601725B (zh) * 2012-08-27 2017-10-11 加拓科學公司 取代的氮雜吲哚化合物及其鹽、組合物和用途
CA2887058C (en) * 2012-10-03 2022-02-22 Exosome Diagnostics, Inc. Use of microvesicles in diagnosis, prognosis, and treatment of medical diseases and conditions
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
KR20150140728A (ko) * 2013-04-15 2015-12-16 리제너론 파마슈티칼스 인코포레이티드 항암요법에 대한 종양 세포 반응의 표지들
CN103941016B (zh) * 2013-05-07 2016-04-27 上海良润生物医药科技有限公司 半胱氨酸蛋白酶抑制剂sn与癌胚抗原的联合应用
US20160116480A1 (en) * 2013-05-13 2016-04-28 Institut Gustave Roussy Prognosis and predictive biomarkers and biological applications thereof
EP3074536B1 (en) 2013-11-25 2019-06-19 Children's Hospital Medical Center Temporal pediatric sepsis biomarker risk model
PE20160993A1 (es) * 2013-12-12 2016-10-14 Abbvie Stemcentrx Llc Nuevos anticuerpos anti-dpep3 y metodos de uso
WO2015101988A1 (en) 2013-12-31 2015-07-09 Yeda Research And Development Co. Ltd. Diagnosis of systemic lupus erythematosus using oligonucleotides antigens
EP3126521B1 (en) * 2014-04-04 2019-03-20 Crown Bioscience, Inc. (Taicang) Hnf4g-rspo2 fusion gene
GB201408100D0 (en) * 2014-05-07 2014-06-18 Sec Dep For Health The Detection method
WO2016011065A1 (en) * 2014-07-15 2016-01-21 Salk Institute For Biolofical Studies Detecting dixdc1 (dix domain-containing protein 1) expression to determine if a tumor will respond to fak and src kinase inhibitors
CN104502603B (zh) * 2014-12-03 2016-04-06 上海交通大学医学院附属上海儿童医学中心 Myo1d作为诊断动脉导管闭合或开放的标志物
CN105986023B (zh) * 2015-02-17 2021-01-05 上海交通大学医学院附属上海儿童医学中心 急性淋巴细胞白血病耐药复发相关突变基因及其应用
WO2016131420A1 (zh) 2015-02-17 2016-08-25 上海交通大学医学院附属上海儿童医学中心 急性淋巴细胞白血病耐药复发相关突变基因及其应用
US11047855B2 (en) 2015-03-01 2021-06-29 Immunarray Ltd. Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
CN105063183A (zh) * 2015-07-22 2015-11-18 浙江理工大学 泛素化途径相关基因在作为用于预测乳腺癌新辅助化疗疗效的生物标记物的应用
US20180231565A1 (en) * 2015-08-09 2018-08-16 Immunarray Ltd Methods for determining the risk of a systemic lupus erythematosus (sle) patient to develop neuropsychiatric syndromes
WO2017027672A1 (en) * 2015-08-12 2017-02-16 Celgene Corporation Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
CN105126080A (zh) * 2015-09-29 2015-12-09 武汉大学 锌指蛋白436（znf436）在治疗心肌肥厚中的应用
CN105671158B (zh) * 2016-02-29 2019-01-18 北京泱深生物信息技术有限公司 Fam63b基因在制备诊治子宫肌瘤的产品中的用途
CN105695617A (zh) * 2016-04-22 2016-06-22 王冬国 乳头状癌的肿瘤标志物及其应用
CN109414448B (zh) 2016-06-17 2021-10-26 豪夫迈·罗氏有限公司 用于减少PAPD5或PAPD7 mRNA治疗乙型肝炎感染的核酸分子
EP3500257B1 (en) * 2016-08-17 2025-07-02 Icahn School of Medicine at Mount Sinai Kinase inhibitor compounds, compositions, and methods of treating cancer
CN108300783A (zh) * 2017-01-11 2018-07-20 上海易毕恩基因科技有限公司 用于筛选肠癌和/或胃癌的基因标志物的方法、用该方法筛选的基因标志物及其用途
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
SG11201907887SA (en) * 2017-03-15 2019-09-27 Eisai Co Ltd Spliceosome mutations and uses thereof
CN109081866B (zh) * 2017-06-13 2021-07-16 北京大学 癌症中的t细胞亚群及其特征基因
CN113684275B (zh) * 2017-06-22 2024-02-27 北海康成（北京）医药科技有限公司 预测食管癌对抗erbb3抗体治疗的应答的方法和试剂盒
UA126931C2 (uk) 2017-10-16 2023-02-22 Ф. Хоффманн-Ля Рош Аг МОЛЕКУЛИ НУКЛЕЇНОВИХ КИСЛОТ ДЛЯ ЗМЕНШЕННЯ РІВНЯ мРНК PAPD5 І PAPD7 ДЛЯ ЛІКУВАННЯ ІНФЕКЦІЙНОГО ГЕПАТИТУ B
CN109825508A (zh) * 2017-11-23 2019-05-31 深圳市第三人民医院 一种用来评估艾滋病合并结核感染的生物标记物
CN109870576B (zh) * 2017-12-05 2021-08-10 中国科学院大连化学物理研究所 Usp10蛋白的定量检测在原发性肝癌预后判断试剂盒中的应用
US12054558B2 (en) * 2018-05-23 2024-08-06 The Jackson Laboratory Anti-NGly-1 antibodies and methods of use
CN108707628B (zh) * 2018-05-28 2021-11-23 上海海洋大学 斑马鱼notch2基因突变体的制备方法
CN108753834B (zh) * 2018-05-28 2021-11-23 上海海洋大学 ddx27基因缺失斑马鱼突变体的制备方法
CN108676867B (zh) * 2018-06-06 2020-06-09 青岛泱深生物医药有限公司 诊治子痫前期的vwce基因及其应用
CN108624678B (zh) * 2018-06-26 2020-07-17 青岛泱深生物医药有限公司 一种用于子痫前期诊治的生物标志物
CN108841960B (zh) * 2018-07-12 2022-02-01 吉林大学 一种结肠腺癌易感性预测试剂盒及系统
CN109468320A (zh) * 2018-11-13 2019-03-15 复旦大学附属中山医院 一种环状rna及其在肝癌诊断中的应用
WO2020117715A1 (en) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment
CN111467493A (zh) * 2019-01-23 2020-07-31 首都师范大学 人rev3l蛋白切割抑制剂及其应用
CN111896740B (zh) * 2019-05-06 2025-02-11 山东大学 诊断或预测生育缺陷的试剂盒
JP2022543722A (ja) * 2019-08-16 2022-10-14 センター フォー エクセレンス イン ブレイン サイエンス アンド インテリジェンス テクノロジー，チャイニーズ アカデミー オブ サイエンシーズ 機能的ニューロン死に関連する神経系疾患の予防および／または治療におけるＰｔｂｐ１阻害剤の使用
CN110551819B (zh) * 2019-08-23 2023-05-16 伯克利南京医学研究有限责任公司 一组卵巢癌预后相关基因的应用
CN110408706B (zh) * 2019-08-30 2023-04-11 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种评估鼻咽癌复发的生物标志物及其应用
CN110643571B (zh) * 2019-10-22 2021-07-27 康妍葆(北京)干细胞科技有限公司 人角蛋白6a在干细胞培养中的应用及产品
KR102261606B1 (ko) * 2019-11-07 2021-06-07 (주)지노믹트리 대장암 검출 방법
CN110819714B (zh) * 2019-11-22 2023-01-10 南方医科大学深圳医院 一种抑癌基因及其应用
US12287338B2 (en) 2019-11-27 2025-04-29 Ascentage Pharma (Suzhou) Co., Ltd. Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway
CN116194121A (zh) * 2020-06-09 2023-05-30 吉尼松公司 用于治疗扩张型心肌病的cilp-1抑制剂
CN111781358A (zh) * 2020-07-13 2020-10-16 张瑜 Xab2蛋白作为卵巢癌预后和/或预测铂类耐药标志物
CN113943798B (zh) * 2020-07-16 2023-10-27 中国农业大学 一种circ RNA作为肝细胞癌诊断标志物及治疗靶点的应用
WO2022076634A1 (en) * 2020-10-08 2022-04-14 The Trustees Of Dartmouth College Methods and agents for treating, preventing, diagnosing, and evaluating therapy for fibrotic, autoimmune, and inflammatory conditions
CN112816708B (zh) * 2021-02-02 2022-05-31 中南大学湘雅二医院 一种预测食管鳞癌患者对化疗药物敏感性的蛋白指标及应用
CN112691195B (zh) * 2021-02-02 2023-03-14 黑龙江省科学院高技术研究院 Prpf8表达抑制剂在制备治疗肺癌的药物中的应用
CN112816711B (zh) * 2021-03-17 2024-04-19 中国医科大学附属盛京医院 用于神经管畸形、先天性心脏病和唇腭裂胎儿产前无创诊断的分子标志物及其应用
CN113373220A (zh) * 2021-05-08 2021-09-10 首都医科大学 与非小细胞肺癌预后相关的标志分子
CN113416739B (zh) * 2021-06-24 2022-04-19 黑龙江八一农垦大学 鲁氏酵母菌基因在提高微生物产hdmf的产量中的应用
CN113667749A (zh) * 2021-08-03 2021-11-19 广东省人民医院 四个关键基因组合评估乳腺癌风险的诊断试剂盒
CN113866424A (zh) * 2021-09-14 2021-12-31 哈尔滨医科大学 碳酸酐酶1和酸性鞘磷脂酶样磷酸二酯酶3a作为分子标志物在结直肠癌诊断中的应用
CN113897437B (zh) * 2021-11-30 2024-06-04 深圳市人民医院 检测样本中标志物表达水平的试剂在制备用于诊断乳腺癌的试剂盒中的应用
CN114592059A (zh) * 2022-01-11 2022-06-07 南方医科大学南方医院 一种评估5-fu治疗敏感性/耐药性的试剂盒
CN114525342B (zh) * 2022-03-03 2025-02-14 温州医科大学附属第一医院 Linc02806在肝细胞癌诊断和治疗中的应用
JP2025509620A (ja) * 2022-03-16 2025-04-11 上海施江生物科技有限公司 含窒素複素環化合物とその使用
CN114672551B (zh) * 2022-05-17 2023-03-31 中国医科大学附属第一医院 Mat2a和mat2b作为检测或治疗良性前列腺增生的药物靶点的应用
CN115389764A (zh) * 2022-07-28 2022-11-25 宁波大学 蛋白质fbxo7在制备子宫内膜癌诊断标志物中的应用
CN115948529A (zh) * 2022-08-01 2023-04-11 湖南家辉生物技术有限公司 一种Cornelia de Lange综合征1型的致病基因、引物对及其应用
CN116179691A (zh) * 2022-09-07 2023-05-30 苏州大学附属第一医院 一种胃癌组合标志物及标志物模型的建立方法
WO2024107924A2 (en) * 2022-11-17 2024-05-23 Board Of Regents, The University Of Texas System A blood-based lipid biomarker panel for personalized risk assessment of breast cancer
CN115948537B (zh) * 2022-12-19 2024-04-09 湖南家辉生物技术有限公司 一种基因chst3复合杂合突变的应用及检测试剂和应用
CN116287253B (zh) * 2023-02-22 2024-06-28 武汉科技大学 一种肺癌分子标志物及其应用
CN116500266B (zh) * 2023-03-07 2025-06-17 南通大学附属医院 MRPS21基因及其RNAi干扰系统的应用
CN116430048B (zh) * 2023-03-07 2025-06-20 南通大学附属医院 BTF3L4基因及其RNAi干扰系统的应用
CN117100866B (zh) * 2023-03-31 2025-10-28 兰州大学第二医院 一种抗肿瘤血管生成药物增效剂、抗肿瘤药物组合物及应用
CN116769916B (zh) * 2023-06-27 2025-03-07 南通大学附属医院 Tmed8基因在制备胰腺癌药物及其诊断试剂盒中的应用
CN116747215A (zh) * 2023-07-14 2023-09-15 新疆医科大学第三附属医院 V-9302在抑制肝癌和增强索拉菲尼抑癌作用中的应用
CN117257919B (zh) * 2023-11-10 2024-10-01 南通大学附属医院 Tbc1d15在筛选或制备保护肝脏的药物中的应用
CN117821469B (zh) * 2023-11-22 2024-08-02 扬州大学 一种鸡trim45截短体重组蛋白或其多克隆抗体的应用
CN118045083B (zh) * 2024-04-15 2024-06-18 哈尔滨医科大学 L-脯氨酸在制备防治非酒精性脂肪肝病药物中的新用途
CN118879858B (zh) * 2024-06-27 2025-09-30 中国科学院合肥物质科学研究院 一组用于预测非小细胞肺癌放疗预后的基因标签及应用
CN120636556A (zh) * 2025-05-07 2025-09-12 武汉科技大学 一种筛选转录调控元件的方法及其应用
CN120442707B (zh) * 2025-07-14 2025-09-09 三亚中国农业科学院国家南繁研究院 棉花耐旱性和耐低温性相关蛋白GhCOX11及其应用
CN121559090B (zh) * 2026-01-08 2026-04-17 山东大学 完全性葡萄胎的生物标志物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030119769A1 (en) * 1994-05-31 2003-06-26 Monia Brett P Antisense oligonucleotide modulation of raf gene expression
US20040018570A1 (en) * 1999-09-01 2004-01-29 Brown University Kinase inhibitors and methods of use in screening assays and modulation of cell proliferation and growth
WO2004087941A1 (en) * 2002-02-15 2004-10-14 The General Hospital Corporation Map-kinase inhibitors as regulators of tumor-associated antigen expression
JP2006518031A (ja) * 2002-09-30 2006-08-03 バイエル・フアーマシユーチカルズ・コーポレーシヨン ガンの予測および予後、ならびにガン治療を監視するための方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US6358932B1 (en) * 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6391636B1 (en) * 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
AU728701B2 (en) * 1996-05-23 2001-01-18 Applied Research Systems Ars Holding N.V. Compounds that inhibit the binding of Raf-1 or 14-3-3 proteins to the beta chain of IL-2 receptor, and pharmaceutical compositions containing same
AR012634A1 (es) * 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6187799B1 (en) * 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US7351834B1 (en) * 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6610484B1 (en) * 1999-01-26 2003-08-26 Cytyc Health Corporation Identifying material from a breast duct
US20040224302A1 (en) * 2002-07-16 2004-11-11 Thomas Jessel Systems and methods for screening for modulators of neural differentiation
WO2007013671A2 (en) * 2005-07-27 2007-02-01 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
PE20070335A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030119769A1 (en) * 1994-05-31 2003-06-26 Monia Brett P Antisense oligonucleotide modulation of raf gene expression
US20040018570A1 (en) * 1999-09-01 2004-01-29 Brown University Kinase inhibitors and methods of use in screening assays and modulation of cell proliferation and growth
WO2004087941A1 (en) * 2002-02-15 2004-10-14 The General Hospital Corporation Map-kinase inhibitors as regulators of tumor-associated antigen expression
JP2006518031A (ja) * 2002-09-30 2006-08-03 バイエル・フアーマシユーチカルズ・コーポレーシヨン ガンの予測および予後、ならびにガン治療を監視するための方法

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013537544A (ja) * 2010-08-17 2013-10-03 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗癌剤併用療法
US10260097B2 (en) 2011-06-02 2019-04-16 Almac Diagnostics Limited Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent
JP2015502958A (ja) * 2011-12-09 2015-01-29 オンコメッド ファーマシューティカルズ インコーポレイテッド がんの処置のための併用療法
JP2015536667A (ja) * 2012-12-03 2015-12-24 アルマック・ダイアグノスティクス・リミテッドＡｌｍａｃ Ｄｉａｇｎｏｓｔｉｃｓ Ｌｉｍｉｔｅｄ 癌のための分子診断検査
US11091809B2 (en) 2012-12-03 2021-08-17 Almac Diagnostic Services Limited Molecular diagnostic test for cancer
JP2016528914A (ja) * 2013-08-28 2016-09-23 クラウン バイオサイエンス インコーポレイテッド（タイカン） 対象のマルチキナーゼ阻害剤に対する応答性を予測する遺伝子発現シグネチャ、及びその使用
US11136625B2 (en) 2013-08-28 2021-10-05 Crown Bioscience, Inc. (Taicang) Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
JP2019216716A (ja) * 2013-12-06 2019-12-26 セルジーン コーポレイション びまん性大細胞型ｂ細胞リンパ腫、多発性骨髄腫、及び骨髄癌の治療の薬効を決定するための方法
JP7142612B2 (ja) 2013-12-06 2022-09-27 セルジーン コーポレイション びまん性大細胞型ｂ細胞リンパ腫、多発性骨髄腫、及び骨髄癌の治療の薬効を決定するための方法
US10280468B2 (en) 2014-02-07 2019-05-07 Almac Diagnostics Limited Molecular diagnostic test for predicting response to anti-angiogenic drugs and prognosis of cancer
JP2017533727A (ja) * 2014-10-13 2017-11-16 セルジーン コーポレイション 固形腫瘍の治療方法及び免疫調節療法への臨床的感度の予測因子としてのバイオマーカーの使用
JP2019518426A (ja) * 2016-04-15 2019-07-04 ジェネンテック， インコーポレイテッド がんの診断及び治療方法

Also Published As

Publication number Publication date
JP2013128487A (ja) 2013-07-04
EP2074226A2 (en) 2009-07-01
WO2008082730A2 (en) 2008-07-10
WO2008082730A3 (en) 2009-01-08
KR20090071603A (ko) 2009-07-01
SG174826A1 (en) 2011-10-28
US20100004253A1 (en) 2010-01-07
CN101541977A (zh) 2009-09-23
MX2009002936A (es) 2009-04-01
AU2007340265B2 (en) 2012-07-26
BRPI0716944A2 (pt) 2013-09-17
AU2007340265A1 (en) 2008-07-10
IL197450A0 (en) 2009-12-24
RU2009114745A (ru) 2010-10-27
CA2662508A1 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
JP2010504530A (ja) Ｒａｆ阻害剤の標的調節、効果、診断、および／または予後診断のためのバイオマーカー
Prabhu et al. Dopamine receptor D5 is a modulator of tumor response to dopamine receptor D2 antagonism
Holohan et al. Cancer drug resistance: an evolving paradigm
JP6290237B2 (ja) 癌を処置するための組成物および方法
US20190134004A1 (en) Methods and compositions for treating breast and prostate cancer
CN101999002A (zh) 诊断和治疗parp-介导的疾病的方法
AU2014229424B2 (en) Markers associated with Wnt inhibitors
Wroblewska et al. SF3B1, NRAS, KIT, and BRAF mutation; CD117 and cMYC expression; and tumoral pigmentation in sinonasal melanomas: an analysis with newly found molecular alterations and some population-based molecular differences
US12325880B2 (en) Identification of PDE3 modulator responsive cancers
US20160102367A1 (en) Recurrent mutations in epigenetic regulators, rhoa and fyn kinase in peripheral t-cell lymphomas
KR20150008926A (ko) 암 세포를 표피 성장 인자 억제제에 대해 감작화시키는 히스톤 데아세틸라제 억제제
CN108026588A (zh) Fgfr表达以及对fgfr抑制剂的敏感性
CA3166386A1 (en) Treatment of cancer with cdk12/13 inhibitors
RS61745B1 (sr) Inhibitori farneziltransferaze za upotrebu u tretiranju kancera
Chu et al. Kinase fusion–related thyroid carcinomas: towards predictive models for advanced actionable diagnostics
TWI885019B (zh) 用於預測靶向細胞凋亡途徑的化合物的抗癌功效的方法和組合物
CN1721553A (zh) 用于评估和治疗癌症的方法
CN111433375A (zh) 选择针对癌症患者的治疗的方法
Freywald et al. Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance
TW202108575A (zh) 用於預測bcl-2/bcl-xl抑制劑對癌症的功效的方法和組合物
Akabane et al. The future of molecular analysis in melanoma: diagnostics to direct molecularly targeted therapy
US12560609B2 (en) Biomarkers predictive of cancer cell response to ML329 or a derivative thereof
CN1626679A (zh) 评估和治疗癌症的方法
WO2025217307A1 (en) Methods for predicting response to a ras(on) inhibitor and combination therapies
HK40053534A (en) Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100909

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100909

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121227

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131029